Clinical Trials Logo

Albuminuria clinical trials

View clinical trials related to Albuminuria.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05570305 Enrolling by invitation - Clinical trials for Chronic Kidney Diseases

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

ZODIAC
Start date: October 6, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.

NCT ID: NCT04889183 Enrolling by invitation - Obesity Clinical Trials

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

SMART
Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.

NCT ID: NCT04295889 Enrolling by invitation - Albuminuria Clinical Trials

Towards HOMe-based Albuminuria Screening: an Implementation Study Testing Two Approaches

THOMAS
Start date: November 14, 2019
Phase: N/A
Study type: Interventional

Chronic Kidney Disease (CKD) is a worldwide major public health problem that is associated with an increased incidence of kidney failure and cardiovascular events, that lead a high burden for affected patients and high costs for society. Symptoms of CKD occur late, when kidney function drops to below 30%. At that time preventive measures will have only limited efficacy. Protein excretion in urine has increasingly been recognized as early marker of CKD, and is often associated with high blood pressure, diabetes, and/or high cholesterol levels. These are all important risk factors for progression of kidney and cardiovascular disease. Population screening for urinary protein loss could detect a considerable number of subjects with yet unknown risk factors for progressive kidney and cardiovascular disease who can benefit of early intervention. However, there is no validated method for population screening yet. The aim is to to develop a home based population screening for elevated urinary protein loss. Two screening methods will be investigated, and yield and cost-effectiveness of these screening methods will be evaluated

NCT ID: NCT02462369 Enrolling by invitation - Microalbuminuria Clinical Trials

Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients

Start date: June 2015
Phase: Phase 4
Study type: Interventional

This study compare the effects on microalbuminuria improvement in type 2 diabetes mellitus (T2DM) treated with saxagliptin or glimepiride.All patients received metformin and/or acarbose, and randomly receive saxagliptin (5mg/d) or glimepiride (1-4mg/d).

NCT ID: NCT01316068 Enrolling by invitation - Clinical trials for Diabetic Nephropathy

Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients

Soften
Start date: March 2011
Phase: Phase 4
Study type: Interventional

Current therapies targeting albuminuria in diabetic nephropathy leave residual urinary albumin secretion, which meanwhile leave residual cardiovascular risk. Previous studies demonstrated that sulodexide could reduce albuminuria in type 2 diabetic patients. But no data concerning Chinese population is available. The investigators aim to provide evidence of effects of sulodexide on diabetic nephropathy in Chinese diabetic patients. Further the investigators also test the hypothesis that sequential administration of intravenous and oral replacement of the drug would gain an earlier and greater reduction of albuminuria, compared with oral use only.